jnj-70218902
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2020 (NCT04397276)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06788509 | Phase 1 | Dec 30, 2024 | Johnson and Johnson |
| NCT04397276 | Phase 1 | Jun 25, 2020 | Janssen Pharmaceutica NV |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2020 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1